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We explored the possible augmenting effect of traumatic brain injury (TBI) history on HIV (human immunod-
eﬁciency virus) associated neurocognitive complications. HIV-infected participants with self-reported history of
deﬁnite TBI were compared to HIV patients without TBI history. Groups were equated for relevant demographic
and HIV-associated characteristics. The TBI group evidenced signiﬁcantly greater deﬁcits in executive functioning
and working memory. N-acetylaspartate, a putative marker of neuronal integrity, was signiﬁcantly lower in the
frontal gray matter and basal ganglia brain regions of the TBI group. Together, these results suggest an additional
brain impact of TBI over that from HIV alone. One clinical implication is that HIV patients with TBI history
may need to be monitored more closely for increased risk of HIV-associated neurocognitive disorder signs or
symptoms.
Keywords: Head injury; HIV associated neurocognitive disorder; Neuropsychological performance; Magnetic
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INTRODUCTION
Though not known as a primarily neurodegenerative
disease, human immunodeﬁciency virus (HIV) infec-
tion has been linked to cognitive impairment as well
as cerebral metabolic changes. HIV has been shown
to cause signiﬁcant impairments of varying severity in
higher order brain functions (HIV-associated neurocog-
nitive disorders: HAND). Currently, a set of research
diagnostic criteria have been proposed to categorize
HAND into three conditions: asymptomatic neurocog-
nitive impairment, HIV-associated mild neurocognitive
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disorder, and HIV-associated dementia (Antinori et al.,
2007). Neuropsychological deﬁcits in attention and learn-
ing have the highest prevalence (61% and 57%, respec-
tively) in HIV+ patients (Grant, 2008); as HIV disease
progresses from early to later stages, executive function-
ing, information-processing speed, and motor function-
ing are associated with the greatest decline (Reger, Welsh,
Razani, Martin, & Boone, 2002).
The precise neuroanatomical basis of the cognitive
effects of HIV is still uncertain. Structural and func-
tional brain imaging has revealed loss of gray and white
matter volumes, increased white matter abnormality, and
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changes in perfusion and glucose metabolism associ-
ated with HIV (Wohlschlaeger, Wenger, Mehraein, &
Weis, 2009). One indication of neuronal injury is reduced
N-acetylaspartate (NAA), a putative marker of neuronal
health and integrity, on magnetic resonance spectroscopy
(MRS) imaging (Schuff et al., 2006). Increased HIV viral
load and decreased CD4+ T-cell counts have been asso-
ciated with decreased levels of NAA in the frontal white
matter, frontal gray matter, and basal ganglia regions,
suggesting that HIV infection may result in loss of neu-
ronal integrity (Taylor et al., 2007). Even when asymp-
tomatic, persons with HIV infection may have decreased
NAA levels in the basal ganglia region (Paul et al., 2007).
With advanced ARV (antiretroviral) regimens, HIV-
infected individuals are living longer and in better health
now than before. Paradoxically, HAND remains preva-
lent. For example, a recent study by the CHARTER
(CNS HIV Antiretroviral Therapy Effects Research,
where CNS denotes central nervous system) group
reported that 40–50% of people in HIV care, with the
majority receiving HAART (highly active antiretrovi-
ral therapy), have neurocognitive impairments (Heaton
et al., in press). While the reasons for HAND persis-
tence are unclear, one possibility is that certain coexisting
(comorbid) factors might increase the brain’s vulnerabil-
ity to HIV injury. Among such comorbidities, traumatic
brain injury (TBI) is commonplace.
Since TBI still remains as a largely unexplored con-
dition within the HIV population, we were interested in
its potential effects in HIV-infected people. TBIs involve
disruption of normal brain function that can be caused
by a physical insult to the head, subjecting it to sudden
acceleration and deceleration forces (Silver, McAllister, &
Arciniegas, 2009). The incidence of new TBIs each year
in the United States is 2 million, which is approximately
35 times greater than the incidence of new HIV infection
peryear(CentersforDiseaseControl,2009a,2009b).The
high prevalence of TBI in the general population sug-
gests that TBI may be a common comorbidity in HIV+
persons that requires further investigation.
The prevalence of HIV+ patients who have suffered
from at least one TBI has not been reported system-
atically. However, in the 1,599 cases studied in the
CHARTER (CNS HIV Antiretroviral Therapy Effects
Research) program at the University of California, San
Diego, approximately 21% reported head injury.
Following a traumatic brain injury, people can expe-
rience a wide range of impairments in the cognitive,
emotional, physical, and psychosocial domains and inter-
actions amongst them (Hernández, 2006). People with
moderate to severe TBI history can experience a range
of cognitive deﬁcits, with one of the most prevalent being
difﬁculty in applying optimal strategies for learning and
memory (Vakil, 2005).
MRSstudieshaveconﬁrmedthatTBIpatientsalsoevi-
dence lower NAA levels (Weiss, Galanaud, Carpentier,
Naccache, & Puybasset, 2007). Mild traumatic brain
injury patients have also been shown to exhibit a 12%
deﬁcit in WBNAA (whole brain N-acetylaspartate), sug-
gesting a loss in neuronal health following a head injury
(B. A. Cohen et al., 2007).
To explore the possibility that TBI might enhance the
effects of HIV on the brain, we performed comprehen-
sive neuropsychological assessments with HIV-infected
persons who did and did not have histories of TBI. We
hypothesized that neurocognitive function in those with
TBI would be worse than in those without, particularly
in areas of cognition that have been implicated in each
etiology—that is, working memory, attention, and exec-
utive function. We also performed a nested study on a
subset of cases to examine changes in brain metabolites
via MRS. Since HIV and TBI are each associated with
decreases in NAA levels, we hypothesized that people
with both HIV and TBI would evidence greater NAA
reductions, suggestive of more neuronal injury.
METHOD
Participants
HIV-infected participants from the multisite CHARTER
study were categorized into either the traumatic brain
injury group (HIV+TBI+) or no traumatic brain injury
group (HIV+TBI–) based on self-reported medical his-
tory. In the CHARTER protocol participants are queried
about head injury on two separate occasions: during
a structured neuromedical history preceding the neuro-
logical examination; and during a neuropsychological
screening that preceded testing. To increase the level
of certainty that a substantial head injury had indeed
occurred, we deﬁned cases as those reporting deﬁnite
head injury on the two different interviews. Out of the
total 1,599 participants in the CHARTER database, 635
participants reported inconsistent information and were
excluded from analysis. The remaining 964 participants
were then categorized into one of the following groups,
in order of increasing severity: no TBI (N = 634); had
concussions or head injuries with brief (i.e., less than
30 minutes) or no loss of consciousness (TBI Level 1,
N = 214); experiencing loss of consciousness greater than
30 minutes (TBI Level 2, N = 93); complicated by neu-
rological deﬁcits lasting greater than 2 weeks (TBI Level
3, N = 17), and having permanent residual neurological
and motor impairments (TBI Level 4, N = 6).
The 214 cases in TBI Level 1 were excluded from anal-
ysis to ensure that only those with deﬁnite a TBI were
analyzed. We also excluded the 6 cases in TBI Level 4 as
they had permanent residua by deﬁnition. The ﬁnal TBI
group (HIV+ TBI+) that we used for analysis included
the 110 participants from either TBI Level 2 or Level
3. All participants were ambulatory patients who had
recovered and were able to both function normally and
participate in the study.
Neuropsychological study
For the neuropsychological study, we selected from the
HIV participants with negative TBI history (HIV+TBI–)
those that matched the HIV+TBI+ on the demographic
characteristics of age, sex, education, and ethnicity,328 LIN ET AL.
TABLE 1
Characteristics of groups with neuropsychological assessment and magnetic resonance spectroscopy subset
NP assessment MRS subset
HIV+TBI+
(N = 110)
HIV+TBI–
(N = 590)
t value
or χ2
p
value
HIV+TBI+
(N = 17)
HIV+TBI–
(N = 84)
t value
or χ2
p
value
Age (years) 43.6 (8.4) 43.6 (8.0) −0.13 .45 47.5 (6.3) 47.1 (5.9) −0.25 .80
Education (years) 12.3 (2.8) 12.6 (2.3) 1.19 .88 13.2 (3.2) 13.1 (2.1) −0.15 .88
WRAT–3
Reading
91.5 (17.3) 90.7 (16.7) −0.47 .32 96.1 (15.9) 93.5 (15.7) −0.61 .54
Sex (% male) 89.2 74.9 12.10 .001 100.0 84.5 5.17 .08
Ethnicity (%
non-White)
56.4 59.5 0.37 .54 58.8 57.1 0.02 .90
No. of ARVs 2.2 (1.5) 2.1 (1.6) −0.55 .29 2.3 (1.6) 2.4 (1.5) 0.37 .71
ARV history (%
currently
using)
69.1 65.6 0.51 .47 70.6 75.0 0.14 .70
% on HAART 69.1 64.4 0.91 .34 70.6 73.8 0.07 .78
Nadir CD4 213.3 (188.5) 219.9 (210.7) 0.31 .62 215.2 (212.4) 174.5 (152.6) −0.93 .35
%A I D S a 60.0 61.5 0.08 .77 64.7 70.2 0.20 .65
Plasma HIVb
(% detectable)
65.1 70.7 1.31 .25 47.1 44.6 0.04 .85
CSF HIVb
(% detectable)
37.4 38.6 0.05 .83 37.5 29.5 0.39 .53
%H C V
seropositive
33.3 31.8 0.10 .75 41.2 33.3 0.38 .54
Note. For t value or χ2 : Variables with standard deviations have a t value; variables with % values have a χ2 value. NP = neuropsy-
chological. MRS = magnetic resonance spectroscopy. WRAT–3 = Wide Range Achievement Test–Third Edition. ARV = antiretroviral.
HAART = highly active antiretroviral therapy. CSF = cerebrospinal ﬂuid. HCV = hepatitis C virus. Standard deviations in parentheses.
aBased on 1993 Centers for Disease Control (CDC) classiﬁcation (Centers for Disease Control, 1992). bBased on limit of detection =
50 copies.
as well as on HIV-associated characteristics of cur-
rent antiretroviral status, antiretroviral history, nadir
CD4, plasma HIV viral loads, CSF (cerebrospinal ﬂuid)
HIV viral loads, AIDS or non-AIDS classiﬁcation, and
presence of hepatitis C (HCV) infection. Wide Range
Achievement Test–Third Edition (WRAT–3) Reading
scores were also used as added matching criteria to
ensure general intellectual equivalence across the groups
(Keogh, Major, Omori, Gándara, & Reid, 1980). This
resulted in a sample of 590 HIV+TBI– and 110
HIV+TBI+ participants whose characteristics are sum-
m a r i z e di nT a b l e1 .
Neuropsychological assessment
The neuropsychological test battery, given to all
CHARTER participants, evaluates eight cognitive abil-
ity areas: overall vocabulary, working memory, executive
functioning, attention and speed of information process-
ing, learning, memory, verbal ﬂuency, and psychomotor
(Table 2; Heaton et al., in press).
Each participant’s level of neuropsychological impair-
ment was determined by calculating deﬁcit scores for
each domain of cognitive functioning. More speciﬁcally,
results for each test were converted to demographically
adjusted T-scores (M = 50, SD = 10) accounting for age,
sex, education, and ethnicity using published normative
conversions. The resulting T-scores were then converted
to deﬁcit scores using the following conversions: T-scores
>40 = deﬁcit score of “0,” T-scores of 35–39 = “1,”
T-scores of 34–30 = “2,” T-scores of 29–25 = “3,”
T-scores of 24–20 = “4,” and T-scores ≤ 19 = “5.” In
addition, a global deﬁcit score (GDS) was calculated to
summarize the overall level of impairment by averaging
the deﬁcit scores across domains. Scores on the GDS
range from 0 to 5 as above, with a higher value signify-
ing a greater level of impairment. A GDS of greater than
0.5 is consistent with deﬁnite mild impairment (Heaton,
Miller, Taylor, & Grant, 2004).
Patient’s self assessment of neurocognitive
functioning
At each visit, participants were administered the Patient’s
Assessment of Own Functioning Inventory (PAOFI),
which asked them to evaluate their own neurocognitive
function. The PAOFI assesses whether or not partici-
pants had complaints about their own functioning in
areas such as sensory, motor, memory, or other cogni-
tive domains and, if so, the level of severity. Scores on the
PAOFI are derived by summing the relevant questions in
each area. The total PAOFI score was obtained by aver-
aging all the other functioning scores (Chelune, Heaton,
& Lehman, 1986).EFFECTS OF TBI AND HIV ON COGNITION AND METABOLITES 329
Depression and substance use assessment
Participants were also compared for potential differ-
ences in depressive symptoms and substance abuse, as
these can have independent effects on neuropsycholog-
ical performance. Depressive symptoms were assessed
using the Beck Depression Inventory (BDI; Richter,
Werner, Heerlein, Kraus, & Sauer, 1998). Participants
were also given a Composite International Diagnostic
Interview (CIDI), which permits diagnosis of partici-
pants with mood disorders according to the Diagnostic
and Statistical Manual of Mental Disorders–Fourth
Edition (DMS–IV; American Psychiatric Association,
1994) criteria (Cooper, Peters, & Andrews, 1998). The
mood disorders speciﬁcally assessed for CHARTER par-
ticipants included major depressive disorder (MDD) and
dysthymia. The CIDI was also used to diagnose a sub-
stance use abuse or dependency disorder, and we deﬁne
“history of substance use disorder” as any individual who
met criteria for substance abuse or dependency, either
c u r r e n t l yo ri nt h ep a s t .D a t aw e r ea l s og a t h e r e do n
currentuseofprescriptionmedicationswithpsychotropic
effects, including antidepressants, sedatives, and opioid
analgesics.
Magnetic resonance spectroscopy (MRS) study
In the CHARTER study, a subset of participants
(HIV+TBI+, N = 17; HIV+TBI–, N = 84) entered a
longitudinal MRS substudy based on their willingness
to participate and not having any contraindications to
MRI imaging (e.g., metal in the body); subjects were not
excluded for any other reason. These participants were
equated on the same characteristics and thus were com-
parable to all subjects in the larger neuropsychological
study (Table 2). The metabolites selected for inspection,
Nacetylaspartate(NAA), myo-inositol(MI),andcholine
(CHO) are thought to reﬂect several neuropathologic
TABLE 2
The neuropsychological battery
Ability area Neuropsychological test Assesses
Overall vocabulary WRAT–3 Reading Premorbid verbal ability
Working memory Paced Auditory Serial Addition Task Ability to work with information in
short-term store WAIS–III Letter–Number Sequencing
Executive functioning Wisconsin Card Sorting Test Abstracting ability (abstract reasoning,
evaluating, planning, and decision making) Trail Making Test Part B
Attention/ speed of
information
processing
WAIS–III Digit Symbol Selecting and evaluating input under time
pressure; associated with speed of
information processing
WAIS–III Symbol Search
Trail Making Test Part A
Learning Hopkins Verbal Learning Test, Learning of explicit and implicit memories,
logical memory, and nonverbal memory Immediate Recall Trials 1–3
Brief Visuospatial Memory Test,
Immediate Recall Trials 1–3
Story Memory Test,
Learning Rate
Trial 1 Recall
Figure Memory Test
Learning Rate
Trial 1 Recall
Memory Hopkins Verbal Learning Test, Delayed recall of explicit and implicit
memories, logical memory, and nonverbal
memory
Delayed Recall
Brief Visuospatial Memory Test,
Delayed Recall
Story Memory Test,
%L o s s
Figure Memory Test
%L o s s
Verbal ﬂuency Controlled Oral Word Association Test Fluency (spontaneous generation of words)
Animal (Category) Fluency Test
Psychomotor Grooved Pegboard Test Performance of motor tasks
Note. WRAT–3 = Wide Range Achievement Test–Third Edition. WAIS–III = Wechsler Adult Intelligence Scale–
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processes relevant to HIV and TBI. NAA is produced by
neuronal mitochondria only and thus serves as a useful
marker for neural integrity. Choline and myo-inositol
indicate inﬂammation and glial changes; these two are
known to be increased in HIV+ patients. Creatine is
a control marker, commonly accepted as a marker of
cellular energy stores (Taylor et al., 2007).
To obtain measurements of these markers, we used
a clinical, General Electric 1.5-Tesla scanner at the 5
CHARTER research sites for short-echo proton mag-
netic resonance spectroscopy. The settings used include
an echo time of 35 ms and a repetition time of 3,000 ms.
The regions of interest (ROIs) were the right frontal lobe
white matter, midline frontal lobe gray matter, and basal
ganglia, including the head of the right caudate nucleus
(Taylor et al., 2007).
Spectral analyses were accomplished using LCModel,
Version 5.2–1. This program analyzes in vivo spectra as
a linear combination of a basis set of complete model
spectra of metabolites in vitro. Metabolite concentra-
tions were calculated correcting for partial volume of
CSF in each ROI. On the day of each scan, a chemical
phantom provided by the CHARTER coordinating cen-
ter was scanned. After processing, metabolites for each
participant were adjusted for site differences by dividing
the in vivo values by the phantom values (Provencher,
1993).
Statistical analysis
Statistical analyses were performed using the JMP
software program (SAS Institute, Inc., Cary, NC).
Neuropsychological and neurological imaging data were
compared between groups with and without reported
head injury using t tests for independent samples. These
analyses were conducted at one-tailed tests based on the a
priori hypotheses presented above. Cohen’s d is reported
as a measure of effect size (J. Cohen, 1988).
RESULTS
On neuropsychological assessments we found that the
HIV+TBI+ group had signiﬁcantly worse deﬁcit scores
than the HIV+TBI– group in working memory and
executive function, and a trend toward worse overall
performance as reﬂected in the GDS (Table 3). Executive
function (Cohen’s d = 0.20), working memory (Cohen’s
d = 0.21), and GDS (Cohen’s d = 0.14) all exhibit a
small effect size. The remaining cognitive ability areas
(attention and speed of information processing, learning,
memory, verbal ﬂuency, and psychomotor) showed no
signiﬁcant differences between the two groups (Table 3).
On self-assessment the HIV+TBI+ group reported
more total complaints on the PAOFI (Cohen’s d = 0.21),
with signiﬁcantly elevated scores in the areas of memory
(Cohen’s d = 0.31) and sensory functioning (Cohen’s d =
0.25); all effect sizes for the PAOFI were small (Table 3).
In the MRS study, the HIV+TBI+ group displayed
signiﬁcantly lower NAA levels in frontal gray matter and
basalganglia,butnotinfrontalwhitematter,thandidthe
HIV+TBI–group(Table4).Frontalgraymatter(Cohen’s
d = 0.59) and basal ganglia (Cohen’s d = 0.58) exhibit
a medium effect. Between the two groups, myo-inositol,
creatine, and choline were not found to be signiﬁcantly
different (Table 4).
The only signiﬁcant correlations between neuropsy-
chological (NP) and MRS values were between frontal
gray matter (FGM) NAA and GDS. The correlation
between FGM NAA and GDS for the TBI group was r =
.55, p = .02, while the correlation for the group without
TABLE 3
NP and PAOFI data comparisons between TBI and non-TBI groups
HIV+TBI+ (N = 110) HIV+TBI– (N = 590) t value p value
NP deﬁcit score
Working memory 0.71 (0.97) 0.54 (0.76) −2.02 .02∗
Executive function 0.73 (1.07) 0.56 (0.81) −1.89 .03∗
Attention/speed of information processing 0.36 (0.73) 0.31 (0.63) −0.77 .22
Learning 0.96 (1.11) 0.83 (1.01) −1.22 .11
Memory 0.70 (1.01) 0.73 (1.03) 0.33 .63
Verbal ﬂuency 0.39 (0.69) 0.36 (0.70) −0.38 .35
Psychomotor 0.59 (0.98) 0.53 (0.92) −0.66 .26
Global 0.62 (0.65) 0.54 (0.57) −1.31 .09
PAOFI
Memory 3.06 (2.91) 2.19 (2.81) −2.98 .002∗
Cognitive 1.48 (2.23) 1.23 (2.20) −1.05 .15
Language 2.13 (2.51) 1.71 (2.50) −1.60 .06
Motor 0.46 (0.86) 0.44 (0.71) −0.34 .37
Sensory 0.61 (0.84) 0.42 (0.73) −2.44 .007∗
Total score 7.25 (7.36) 5.71 (7.29) −2.03 .02∗
Note. Standard deviations in parentheses. NP = neuropsychological. Patient’s Assessment of Own Functioning Inventory. TBI =
traumatic brain injury. p < .05.EFFECTS OF TBI AND HIV ON COGNITION AND METABOLITES 331
TABLE 4
MRS data comparison between TBI and no-TBI groups
HIV+ TBI+ N = 17 HIV+TBI– N = 84 t value p value
Frontal white matter N-Acetylaspartate 1.18 (0.13) 1.21 (0.14) 0.85 .20
myo-inositol 1.71 (0.34) 1.63 (0.40) −0.84 .20
Creatine 1.01 (0.20) 0.97 (0.15) −0.75 .23
Choline 1.06 (0.17) 0.98 (0.18) −1.56 .06
Frontal gray matter N-Acetylaspartate 1.04 (0.16) 1.12 (0.13) 2.18 .02∗
myo-inositol 1.31 (0.33) 1.42 (0.28) 1.48 .93
Creatine 1.00 (0.19) 1.02 (0.15) 0.56 .29
Choline 0.79 (0.19) 0.78 (0.14) −0.39 .35
Basal ganglia N-Acetylaspartate 1.21 (0.17) 1.29 (0.13) 2.17 .02∗
myo-inositol 1.35 (0.21) 1.41 (0.26) 0.73 .77
Creatine 1.17 (0.25) 1.21 (0.21) 0.69 .25
Choline 0.99 (0.18) 0.97 (0.15) −0.48 .32
Note. Standard deviations in parentheses. MRS = magnetic resonance spectroscopy. TBI = traumatic brain injury.
p < .05.
TBI was r = .32, p = .003. Fisher’s r-to-z transformation
was used to test the difference between these two correla-
tions, which were not signiﬁcantly different even using a
one-sided test (p = .16).
Depressive symptoms (BDI scores) did not signif-
icantly differ between HIV+TBI+ and HIV+TBI–
groups (Table 5). Alcohol use disorders were somewhat
more prevalent in HIV+TBI+ (61.7% vs. 51.2% for
HIV+TBI–). The other substance categories (cannabis,
cocaine, methamphetamine, opioid, hallucinogen,
sedative, and inhalants) showed no statistically signiﬁ-
cant differences between groups (Table 5). There was no
signiﬁcant difference in the proportions of participants
with lifetime history of mood disorders (57.4% for TBI+;
51.5% for TBI–) or with mood disorders at time of
evaluation (18.2% for TBI+; 15.1% for TBI–).
Although the difference in proportion with alcohol dis-
orders was not large, we conducted a series of two-way
analyses of variance (ANOVA) with TBI and alcohol
disorder as independent variables and the various neu-
ropsychological, PAOFI, and MRS scores as dependent.
None of the 2 × 2 ANOVAs for the NP deﬁcit and
PAOFI scores was statistically signiﬁcant. The R2 values
for each of these models ranged from .001 to .007, mean-
ing that the highest proportion of variance explained was
0.7%. Less than 1% of the variance in MRS measures was
accounted for by the combination of TBI and history of
alcohol use disorder. In the case of FGM NAA, the 2 × 2
ANOVA model was statistically signiﬁcant overall (R2 =
.05, p = .01); however, the interaction between TBI and
history of alcohol use disorder was not statistically signif-
icant (p = .16). In the case of basal ganglia (BG) NAA,
the overall model was statistically signiﬁcant (R2 = .03,
p = .05), and there was a trend towards a signiﬁcant inter-
action between TBI and history of alcohol use disorder
(p = .06). Further analysis revealed that subjects with his-
tory of alcohol use disorder and TBI had the lowest NAA
in the basal ganglia.
TABLE 5
Depression and substance dependence comparisons in TBI and non-TBI groups
HIV+TBI+ (N = 110) HIV+TBI– (N = 590)
t
value χ2
p
value
BDI 15.1 (10.5) 14.1 (13.6) −0.73 .23
With history of use
disorder of:
Alcohol (%) 62.7 51.2 5.02 .03∗
Cannabis (%) 3.6 2.5 0.39 .53
Cocaine (%) 6.4 7.3 0.12 .73
Opioid (%) 1.8 5.4 3.26 .07
Meth (%) 0.91 3.1 2.06 .15
Hallucinogen (%) 0.0 0.17 0.34 .56
Sedative (%) 0.0 0.17 0.34 .56
Inhalant (%) 0.0 0.17 0.34 .56
Note. History of use disorder includes “abuse” and “dependency,” as deﬁned by the Diagnostic and Statistical
Manual of Mental Disorders–Fourth Edition (DSM–IV) criteria, either currently or in the past (American Psychiatric
Association, 1994, 2000). Standard deviations in parentheses. TBI = traumatic brain injury. BDI = Beck Depression
Inventory. p < .05.332 LIN ET AL.
Proportions of participants with diagnoses of multiple
substance use were not signiﬁcantly different between
TBI+ (53.6%) and TBI– (47.6%) groups. There was
also no signiﬁcant difference in proportions with
current psychotropic use between TBI+ (54.5%) and
TBI– (58.1%) groups.
DISCUSSION
The results of this study indicate that HIV-infected par-
ticipants who report substantial TBI, deﬁned as a history
of loss of consciousness greater than 30 minutes or
complicated by neurological symptoms persisting more
than 2 weeks after the injury, were signiﬁcantly more
impaired in working memory and executive function-
ing than the HIV+ TBI– group. Consistent with our
neuropsychological test results, the HIV+TBI+ group
also reported more neurocognitive problems, including
memory and sensory complaints.
From our MRS subset, we found that HIV and TBI
together were associated with decreased NAA in the
frontal gray matter and basal ganglia brain regions when
compared to HIV participants without TBI. Our results
are consistent with studies that have showed decreased
levels of NAA associated with HIV alone and TBI alone;
they also suggest greater reduction in neuronal integrity
in those regions among the HIV+TBI+ group (Taylor
et al., 2007).
Our groups were well equated on many factors that
could have independently contributed to worse NP
performance or metabolite changes. These matching
factors included age, education, race/ethnicity, reading
proﬁciency, and several HIV disease and treatment char-
acteristics, including nadir CD4 count. Though indi-
viduals within the HIV+TBI+ group were somewhat
more likely to be male (89% vs. 75% for HIV+TBI),
our use of gender-adjusted norms available for most
of the neuropsychological tests make it unlikely that
gender inﬂuenced the results. Furthermore, a study on
neuropsychological performance in mild TBI patients
revealed no statistically signiﬁcant differences between
male and female patients (Tsushima, Lum, & Geling,
2009). The groups also had equivalent levels of depressive
symptoms (typically in the mild severity range) as well
as current and past diagnoses of MDD, dysthymia, or
both. Substance disorders were also comparable, with the
exception of alcohol disorders, which were about 10%
higher in the HIV+TBI+ group. However, analyses tak-
ing alcohol disorder diagnosis into account did not reveal
any systematic effect for alcohol on CNS outcomes.
From these data, we believe it is accurate to say that
a history of more than minimal TBI in the setting of
HIV is associated with mild enhancement of neurocog-
nitive symptoms and signs, as well as more evidence of
metabolite change in the brain. At the same time, the
effect sizes for neuropsychological performance are sur-
prisingly small (in the 0.15 range), given that these were
more than minimal injuries by history. The effect sizes
on reported cognition were somewhat higher (0.21 to
0.31) and were not explained by differences in mood.
This, coupled with the more robust effect on the metabo-
lite NAA in the MRS substudy, opens the possibility
that TBI may be associated with more lingering brain
effects than are being captured by neuropsychological
testing.
Our data are also consistent with another study that
demonstrated that people who are HIV+TBI+ have sig-
niﬁcantly greater number of symptoms associated with
mildTBIthandoanHIV+TBI–group.Theauthorsused
the TIRR (The Institute for Rehabilitation Research)
symptom checklist, which included the cluster of 25
symptoms speciﬁc to mild TBI that were higher in those
with previous head injuries (Jaffe, O’Neill, Vandergoot,
Gordon, & Small, 2000). Though the authors were the
ﬁrst to state the importance of recognizing the functional
impact of TBI within the HIV population, our report
has further explored what the impact is through analy-
sisofneuropsychologicaltests,spectroscopyinformation,
depressive symptoms, alcohol and drug abuse, and bio-
logical markers of HIV infection and AIDS disease.
Although the effects of TBI on HIV neurocogni-
tive outcomes have not received wide attention, there
are indications that history of TBI can amplify the
effects of other neurological diseases. For example, trau-
matic brain injury appears to increase the risk of neu-
rodegenerative diseases such as Parkinson’s disease and
Alzheimer’s disease (Formisano et al., 2009; Van Den
Heuvel, Thorton, & Vink, 2007). Persisting difﬁculties
with abstraction associated with alcoholism may also be
ampliﬁed by head injury history (Adams & Grant, 1986).
The mechanisms of the reinforcing effects of HIV
and TBI on brain function are unknown. Reduction in
NAA is consistent with neuronal injury associated with
TBI leading to a disruption of neuronal mitochondrial
activity, which subsequently leads to cognitive compro-
mise. The lower NAA levels may also be compatible
with the common neural injury mechanism of increased
excitotoxicity: TBI alone could potentiate large ﬂuxes of
calcium that induce apoptosis in neurons associated with
cognition (Greenwood, 1991).
TBI has also been associated with inﬂammation
(Cederberg & Siesjö, 2010). However, given that in the
MRS substudy there were no signiﬁcant differences
between HIV+TBI+ and HIV+TBI– in levels of myo-
inositol and choline, metabolites indicative of inﬂam-
mation, it appears that an inﬂammatory process may
not be linked to the TBI-associated cognitive worsen-
ing that follows. Instead, the patterns in our data (e.g.,
NAA reduction in TBI+) suggest that persistent neu-
ronal injury may be a factor. Since TBI has been linked
to increased blood brain barrier (BBB) permeability, it
is possible that mechanisms associated with increased
BBB permeability can enhance HIV’s penetration and
virulence in HIV+TBI+ individuals (Fay et al., 2009;
Moody, 2006). Viral proteins and inﬂammatory medi-
ators could disrupt BBB regulation, allowing increased
leukocyte migration and inducing subsequent neuronal
damage and death (Roberts, Buckner, & Berman, 2010).
Our analyses were based on a study limited to HIV-
infected people. Therefore, though our results are com-
patible with a model of additivity, without examiningEFFECTS OF TBI AND HIV ON COGNITION AND METABOLITES 333
HIV-uninfected groups that have TBI we cannot be cer-
tain whether these are additive or interactive effects.
Because this was an exploratory study, we did not rigor-
ously control for multiple comparisons, and thus the data
must be regarded as preliminary. Furthermore, since our
study was retrospective, some details about the TBIs were
unavailable. It is possible that the TBI group itself dif-
feredinsomewaythatwedidnotaccountfor.Apotential
future prospective study could integrate more clinical
information about a participant’s head injury such as the
location of initial insult, Glasgow Coma Scale rating, or
more precision on duration of unconsciousness. Future
studies could also utilize functional magnetic resonance
imaging (fMRI) information as another means to evalu-
ate neuropsychological performance simultaneously with
metabolic imaging.
Looking at the number of head injuries that a per-
son experienced could also have been worthwhile (such
data were not systematically gathered in CHARTER),
as neuropsychological tests of memory, attention, and
motor function have shown worse performance with
repeated head injury (Hestad, Updike, Selnes, & Royal,
1995). For example, HIV– individuals with multiple TBIs,
when compared to those with a single TBI, exhibit
signiﬁcantly poorer memory and executive functioning
(Belanger, Spiegel, & Vanderploeg, 2010). Given that
these two neurocognitive domains are the same as those
that showed signiﬁcant deﬁcits in our study, it would
be interesting to determine whether there are cumulative
effects of multiple TBI on HIV-associated neurocognitive
decline.
Despite some limitations, our study does indicate that
TBI may increase vulnerability to brain dysfunction in
HIV-infected individuals. If conﬁrmed, the results indi-
cate that those involved with HIV care need to take head
injury into account in their neurological evaluation and
clinical management of HIV patients.
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